Core Points - Teva Pharmaceuticals USA has recalled 580,844 bottles of Prazosin Hydrochloride due to high levels of a potentially cancer-causing chemical compound [1][5][6] - The recall includes various dosages of the medication, specifically 1 mg, 2 mg, and 5 mg, with bottle sizes ranging from 100 to 1,000 capsules [5] - The FDA classified the recall as Class II, indicating that the medication may cause temporary or medically reversible adverse health consequences, but the probability of serious adverse health consequences is remote [6] Company Summary - Teva Pharmaceuticals USA is based in Parsippany, NJ, and is involved in the production of blood pressure medications [1] - The company has not yet provided guidance on whether consumers should dispose of or return the recalled products [6][7] Industry Summary - The recall highlights ongoing concerns regarding the safety of pharmaceutical products and the regulatory oversight by the FDA [5][6] - The presence of high levels of "N-nitroso Prazosin impurity C" raises significant health concerns within the pharmaceutical industry, particularly regarding cancer risks associated with certain medications [5]